LC-MS vs. GC-MS, Online Extraction Systems, Advantages of Technology for Drug Screening Assays

2012 ◽  
pp. 15-27 ◽  
Author(s):  
Pierre Marquet
Keyword(s):  
Drug Screening ◽  
Screening Assays ◽  
Online Extraction

Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS, and LC-MS/MS

2021 ◽  
Author(s):  
Andrii Puzyrenko ◽  
Dan Wang ◽  
Randy Schneider ◽  
Greg Wallace ◽  
Sara Schreiber ◽  
...  
Keyword(s):  
Drug Screening ◽  
Forensic Toxicology ◽  
Confirmatory Testing ◽  
Urine Drug ◽  
Screening Assays ◽  
Us Fda ◽  
Urine Specimens ◽  
Abbott Architect ◽  
Designer Benzodiazepines ◽  
Urine Drug Screening

ABSTRACT This study investigated the presence of designer benzodiazepines in 35 urine specimens obtained from emergency department patients undergoing urine drug screening. All specimens showed apparent false-positive benzodiazepine screening results (i.e., confirmatory testing using a 19-component LC-MS/MS panel showed no prescribed benzodiazepines at detectable levels). The primary aims were to identify the possible presence of designer benzodiazepines, characterize the reactivity of commercially available screening immunoassays with designer benzodiazepines, and evaluate the risk of inappropriately ruling out designer benzodiazepine use when utilizing common urine drug screening and confirmatory tests. Specimens were obtained from emergency departments of a single US Health system. Following clinically ordered drug screening using Abbott ARCHITECT c assays and lab-developed LC-MS/MS confirmatory testing, additional characterization was performed for investigative purposes. Specifically, urine specimens were screened using two additional assays (Roche cobas c502, Siemens Dimension Vista) and LC-QTOF-MS to identify presumptively positive species, including benzodiazepines and non-benzodiazepines. Finally, targeted, qualitative LC-MS/MS was performed to confirm the presence of 12 designer benzodiazepines. Following benzodiazepine detection using the Abbott ARCHITECT, benzodiazepines were subsequently detected in 28/35 and 35/35 urine specimens, respectively, using Siemens and Roche assays. LC-QTOF-MS showed the presumptive presence of at least one non-FDA approved benzodiazepine in 30/35 specimens: flubromazolam (12/35), flualprazolam (11/35), flubromazepam (2/35), clonazolam (4/35), etizolam (9/35), metizolam (5/35), nitrazepam (1/35), and pyrazolam (1/35). Two or three designer benzodiazepines were detected concurrently in 13/35 specimens. Qualitative LC-MS/MS confirmed the presence of at least one designer benzodiazepine or metabolite in 23/35 specimens, with 3 specimens unavailable for confirmatory testing. Urine benzodiazepine screening assays from three manufacturers were cross-reactive with multiple non-US FDA-approved benzodiazepines. Clinical and forensic toxicology laboratories using traditionally designed LC-MS/MS panels may fail to confirm the presence of non-US FDA-approved benzodiazepines detected by screening assays, risking inappropriate interpretation of screening results as false-positives.

Letter: Interference in drug screening assays.

1976 ◽  
Vol 22 (6) ◽  
pp. 933-933 ◽  
Author(s):  
L P Hackett ◽  
L F Dusci
Keyword(s):  
Drug Screening ◽  
Screening Assays

From target identification to drug screening assays for neurodegenerative diseases

2005 ◽  
Vol 52 (3) ◽  
pp. 245-251 ◽  
Author(s):  
C ZUCCATO ◽  
M TARTARI ◽  
D GOFFREDO ◽  
E CATTANEO ◽  
D RIGAMONTI
Keyword(s):  
Neurodegenerative Diseases ◽  
Drug Screening ◽  
Target Identification ◽  
Screening Assays

scholarly journals Quantitative Analysis of Drug Efficacy on C. elegans Models for Neuromuscular Diseases

2021 ◽  
Author(s):  
Samuel Sofela ◽  
Sarah Sahloul ◽  
Yong-Ak Song
Keyword(s):  
Drug Screening ◽  
Low Cost ◽  
Neuromuscular Diseases ◽  
Model Organism ◽  
Drug Efficacy ◽  
Two Dimensional ◽  
C Elegans ◽  
Drug Candidates ◽  
High Throughput Drug Screening ◽  
Screening Assays

AbstractCaenorhabditis elegans has emerged as a powerful model organism for drug screening due to its cellular simplicity, genetic amenability and homology to humans combined with its small size and low cost. Currently, high-throughput drug screening assays are mostly based on image-based phenotyping not exploiting key locomotory parameters of this multicellular model with muscles such as its thrashing force, a critical parameter when screening drugs for muscle-related diseases. In this study, we demonstrated the use of a micropillar-based force assay chip in combination with an imaging assay to evaluate the efficacy of various drugs currently used in treatment of neuromuscular diseases. Using this two-dimensional approach, we showed that the force assay was generally more sensitive in measuring efficacy of drug treatment in Duchenne Muscular Dystrophy and Parkinson’s Disease mutant worms as well as partly in Amyotrophic Lateral Sclerosis model. These results underline the potential of our force assay chip in screening of potential drug candidates for the treatment of neuromuscular diseases when combined with an imaging assay in a two-dimensional analysis approach.

scholarly journals WAT-on-a-chip: a physiologically relevant microfluidic system incorporating white adipose tissue

Lab on a Chip ◽  
2017 ◽  
Vol 17 (9) ◽  
pp. 1645-1654 ◽  
Author(s):  
Peter Loskill ◽  
Thiagarajan Sezhian ◽  
Kevin M. Tharp ◽  
Felipe T. Lee-Montiel ◽  
Shaheen Jeeawoody ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
White Adipose Tissue ◽  
Drug Screening ◽  
Disease Modeling ◽  
Microfluidic System ◽  
Organ Systems ◽  
Screening Assays ◽  
Single Organ

Organs-on-a-chip possess a promising future as drug screening assays and testbeds for disease modeling in the context of both single-organ systems and multi-organ-chips.

Sign in / Sign up

Export Citation Format

Share Document